NASDAQ$VYNE
VYNE Therapeutics INC · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
VYNE's financial performance reflected increased total revenues compared to the previous year, driven by product sales and license revenue.
VYNE Therapeutics reported increased revenues for Q4 2020, driven by the launch of new products and a license agreement. The company is advancing its pipeline with FCD105 in Phase 3 and planning a Phase 2a study for FMX114.
- ZILXI launched nationwide and became available in pharmacies on October 1st.
- Long-term safety and efficacy data for ZILXI was published, demonstrating a favorable safety profile for up to 52 weeks.
- FDA approved AMZEEQ label update with new information indicating the low propensity of P. acnes to develop resistance to minocycline.
- VYNE plans to develop FMX114, a fixed combination of tofacitinib and fingolimod in a topical gel for the potential treatment of mild-to-moderate atopic dermatitis.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$4.29M
Revenue by segment
VYNE · $180K total across 1 segment · Q4 2020
- Royalty revenues$180K—100.0%
Forward guidance
VYNE expects its current cash and cash equivalents, proceeds from recent offerings, and projected cash flows from revenues will be sufficient to fund its ongoing needs through the end of 2022.
Tailwinds
- Sufficient cash to fund operations through the end of 2022.
- Advancement of FCD105 into a Phase 3 program.
- Planned Phase 2a study for FMX114 in atopic dermatitis.
- Continued progress in the trial and utilization of commercially launched products.
- Driving market share in the acne and rosacea categories.
Headwinds
- COVID-19 pandemic and its impact on business operations and liquidity
- Risks of potential litigation by third-parties regarding infringement of third-party intellectual property
- Risks that VYNE’s intellectual property rights may fail to provide adequate protection
- Additional competition in the acne and dermatology markets
- Volatility in stock price may result in rapid and substantial increases or decreases in stock price
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-10.8%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.9% | -15.4% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro